



PATENT CASE: CN01472KB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X
In re Application of: **STAMFORD et al.** : Examiner: To Be Assigned
: :
For Patent: **New Neuropeptide Y** : Date: January 14, 2004
Y5 Receptor Antagonists : :
: Group Art Unit: To Be Assigned
Serial No.: **10/692,559** :
Filed: **10/24/2003** :
-----X

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references ☐ are attached ☒ were filed in related application U.S. Serial No(s) 10/202,239 filed 07/24/2002, respectively.

(b) No fee is believed due because:

- ☐ This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ This Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☒ This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

(c) ☐ This Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or

☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

(d) ☐ This Information Disclosure Statement is being filed on or before the payment of the issue fee; and

☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and


☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365, Patent Case No. CN01472KB.

Respectfully submitted,

SCHERING-PLOUGH CORPORATION

Dated: 01/14/2004
SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530
Facsimile No.: (908) 298-5388

By: 
Name: **William Y. Lee**
Reg. No.: **46,100**
Attorney of Record
Telephone No.: (908) 298-2161

Sheet 1 of 1

FORM TO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CN01472KB

SERIAL NO.:

10/692,559

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:

STAMFORD e tal.

FILING DATE:

10/24/2003

GROUP:

TO BE ASSIGNED

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	4,405,644	09/20/83	Kabbe et al.			
	AB	4,623,662	11/18/86	DeVries			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	AL	WO 96/16542	06/06/96	PCT				
	AM	WO 00/27845	05/18/00	PCT				
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ	Billington et al., Am J. Physiol., 260, R321, 1991
AR	Gehlert, D., Proc. Soc. Exp. Biol. Med., 218, 7, 1998
AS	Gerald, C. et al., Nature, 1996, 382, 168
AT	Hwa, J. et al., Am. J. Physiol., 277 (46), R1428, 1999
AU	Michel, M. et al., Pharmacol. Rev., 50, 143, 1998
AV	Stanley, B. and Leibowitz, S., Proc. Natl. Acad. Sci. USA 82: 3940-3943, 1985
AW	Wahlestedt, C., and Reis, D.J., Ann. Rev. Pharmacol. Toxicol., 32:309-352, 1993
AX	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.